08:00 , Nov 14, 2011 |  BC Week In Review  |  Financial News

Biomoda withdraws best efforts offering

Biomoda Inc. (OTCBB:BMOD), Albuquerque, N.M.   Business: Diagnostic, Cancer   Date announced: 11/7/11   Type: Best efforts offering   Note: Biomoda withdrew the offering, citing unfavorable market conditions.  ...
07:00 , Apr 11, 2011 |  BC Week In Review  |  Company News

Biomoda, UT Health Science Center deal

Biomoda signed a memorandum of understanding with the university's Health Science Center to optimize Biomoda's CyPath lung cancer diagnostic. The porphyrin-based cytology assay that binds to cancer cells and fluoresces red under UV light is...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Clinical News

CyPath: Phase II data

Top-line data from a single-blind, U.S. Phase II trial in sputum samples from 102 high-risk, heavy military veteran smokers and a control group of 26 patients already diagnosed with lung cancer but who have not...
08:00 , Feb 28, 2011 |  BC Week In Review  |  Clinical News

CyPath: Completed Phase II enrollment

Biomoda completed enrollment in a single-blind, U.S Phase II trial of CyPath. In October, the company amended the trial to enroll additional patients after determining that it did not secure sufficient samples in the control...
08:00 , Jan 24, 2011 |  BC Week In Review  |  Financial News

Biomoda proposes best efforts offering

Biomoda Inc. (OTCBB:BMOD), Albuquerque, N.M.   Business: Diagnostic, Cancer   Date announced: 1/14/11   Type: Best efforts offering   To be raised: Up to $3 million   Shares: TBD   Price prior: $0.08   Shares...
08:00 , Jan 10, 2011 |  BC Week In Review  |  Company News

Biomoda Inc management update

Biomoda Inc . (OTCBB:BMOD), Albuquerque, N.M.   Business: Diagnostic, Cancer   Transitioned: Maria Zannes to CEO, while remaining chairman; she replaces John Cousins, who will remain president and CFO  ...
07:00 , Oct 25, 2010 |  BC Week In Review  |  Clinical News

CyPath: Phase II amended

Biomoda amended a single-blind, U.S. Phase II trial of Cypath to enroll additional patients in the control group. The study includes a larger cohort of high-risk, heavy smokers and a smaller, control cohort of patients...
07:00 , Sep 27, 2010 |  BC Week In Review  |  Financial News

Biomoda completes private placement of convertible debentures and warrants

Biomoda Inc. (OTCBB:BMOD), Albuquerque, N.M.   Business: Diagnostic, Cancer   Date completed: 9/21/10   Type: Private placement of convertible debentures and warrants   Raised: $560,000   Investors: Institutional investors   Note: The debentures bear 10%...
07:00 , Jul 5, 2010 |  BC Week In Review  |  Clinical News

CyPath: Completed Phase II enrollment

Biomoda completed patient enrollment in a single-blind Phase II trial. The study includes a larger cohort of high-risk, heavy smokers and a smaller cohort of patients already diagnosed with lung cancer but who have not...
08:00 , Nov 2, 2009 |  BC Week In Review  |  Clinical News

CyPath: Pilot trial completed enrollment

Biomoda completed enrollment of 150 volunteers with a history of heavy smoking in a single-blind, U.S. pilot trial. Biomoda Inc. (OTCBB:BMOD), Albuquerque, N.M.   Product: CyPath , Tetrakis Carboxy Phenyl Porphine (TCPP)   Business: Cancer...